Biotech Values

[DewDiligence]

PFE/MTSR—As a matter of policy, most companies won't comment on matters under litigation. You don't want to inadvertently say something that your adversary might use against you in court. Hence, Bourla’s non-answer regarding MTSR on PFE's 3Q25 CC was par for the course.

p.s. I'm surprised that PFE raised its offer while its request for a TRO is pending at the Delaware Chancery Court.